Numerai’s Treace Medical Concepts TMCI Stock Holding History

Numerai’s Portfolio TMCI Stock Details TMCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-16,564	Closed	-$217K	–	316
2023 Q3	$217K	Buy	+16,564	New	+$303K	0.07%	198

Other funds holding TMCI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DSCM

Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Numerai's TMCI Position: Q4 2023 in Review

Numerai sold out of Treace Medical Concepts (TMCI) in Q4 2023, closing a stake of 16,564 shares — an estimated $217K sold.

Numerai first reported a position in TMCI in Q3 2023 and held it in 1 quarter. The position peaked at $217K in Q3 2023. 127 funds tracked by Wall St. Rank hold TMCI as of Q4 2023.

Numerai reported no remaining Treace Medical Concepts position as of Q4 2023 after selling out during the quarter.
Numerai sold 16,564 Treace Medical Concepts shares in Q4 2023, an estimated $217K.
Numerai first reported a position in Treace Medical Concepts in Q3 2023 and held it in 1 quarter.
Numerai's Treace Medical Concepts position peaked at $217K in Q3 2023.
127 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q4 2023.

Based on Numerai's 13F filing for Q4 2023, filed 14 Feb 2024.